在炎症性肠病中使用多种物质与急诊室访问的风险增加有关:一项纵向研究
Kaleb Bogale1, Izabela Zubrzycka2, August Stuart3
1Department of Medicine, Columbia University Irving Medical Center, New York (Kaleb Bogale).
Annals of gastroenterology
|November 29, 2023
概括
在炎症性肠病 (IBD) 患者中,多种物质的使用与更多的急诊室访问有关. 对多种物质使用 (PSU) 的查对于有效管理IBD患者至关重要.
科学领域:
- 胃肠病学 胃肠病学
- 公共卫生 公共卫生
- 成 药物 药物 药物 药物
背景情况:
- 多种物质使用 (PSU),定义为使用两种或更多物质,在炎症性肠病 (IBD) 患者中很普遍.
- 新出现的证据表明PSU可能与IBD的不良结果相关.
- 这项研究前性地调查了PSU对IBD疾病活动和医疗保健利用的影响.
研究的目的:
- 评估多物质使用 (PSU) 与炎症性肠病 (IBD) 中的疾病活性之间的关联.
- 评估PSU和IBD患者医疗保健资源利用之间的关系.
- 在IBD队列中确定与PSU相关的潜在风险因素和结果.
主要方法:
- 从2015年10月到2019年12月,在一家高等IBD中心进行了前性研究.
- 162名IBD患者在两个时间点进行了评估,评估了人口统计,疾病活性,症状和物质使用 (烟草,酒精,阿片类药物等). ) 的情况.
- 使用多变量后勤回归模型来分析PSU与随访结果之间的关联.
主要成果:
- 在162名IBD患者中,46% (n=75) 在索引访问时使用多种物质 (PSU).
- 公共服务单位与急诊室 (ED) 访问的增加显著相关 (OR 2.51,P=0.01).
- PSU与肠外表现有负相关性 (OR 0.37,P=0.005),没有发现年龄,性别或疾病活性的关联.
结论:
- 使用多种物质 (PSU) 的炎症性肠病患者面临未来紧急诊所访问的风险更高.
- 这些发现强调了在IBD患者护理中常规查物质使用的重要性.
- 实施查协议可以帮助减轻在IBD管理中与PSU相关的风险.
相关概念视频
Inflammatory Bowel Disease I: Ulcerative Colitis
190
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
190
Drugs for Treatment of Diarrhea-Predominant IBS
182
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
182
Chronic Bowel Disorders: Introduction
456
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
456
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
121
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
121
Inflammatory Bowel Disease IV: Pharmacological Management
130
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
130
Inflammatory Bowel Disease II: Crohn's Disease
255
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
255


